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Prostate Tumor Suppressor
C. W. Tam, A. S. Cheng, R. Y. M. Ma, K.-M. Yao, and S. Y. W. Shiu
Departments of Physiology (C.W.T., A.S.C., S.Y.W.S.) and Biochemistry (R.Y.M.M., K.-M.Y.), The University of Hong Kong,
Hong Kong, China
A possible role of the PDZ domain-containing protein 2
(PDZD2) in prostate tumorigenesis has been suggested. Be-
sides, PDZD2 is posttranslationally cleaved by a caspase-
dependent mechanism to form a secreted PDZ domain-
containing protein 2 (sPDZD2) with unknown functions in
humans. In this study, we demonstrate the endogenous ex-
pression of PDZD2 and secretion of sPDZD2 in cancerous
DU145, PC-3, 22Rv1, LNCaP, and immortalized RWPE-1 pros-
tate epithelial cells. Inhibition of endogenous sPDZD2 pro-
duction and secretion by DU145, PC-3, 22Rv1, and RWPE-1
cells via the caspase-3 inhibitor Z-DEVD-FMK resulted in in-
creased cell proliferation, which was abrogated by treatment
with exogenous recombinant sPDZD2. Whereas sPDZD2-
induced antiproliferation in DU145, PC-3, and 22Rv1 cells, it
induced apoptosis in LNCaP cells. The data suggest that en-
dogenous sPDZD2, produced by caspase-3-mediated cleavage
from PDZD2, may function as a novel autocrine growth sup-
pressor for humanprostate cancer cells. The antiproliferative
effect of sPDZD2 was apparently mediated through slowing
the entry of DU145, PC-3, and 22Rv1 cells into the S phase of
the cell cycle. In DU145 cells, this can be attributed to stim-
ulated p53 and p21CIP1/WAF1 expression by sPDZD2. On the
otherhand, theapoptotic effect of sPDZD2onLNCaPcellswas
apparently mediated via p53-independent Bad stimulation.
Together our results indicate the presence of p53-dependent
and p53-independent PDZD2/sPDZD2 autocrine growth sup-
pressive signaling pathways in human prostate cancer cells
and suggest a novel therapeutic approach of harnessing the
latent tumor-suppressive potential of an endogenous auto-
crine signaling protein like sPDZD2 to inhibit prostate cancer
growth. (Endocrinology 147: 0000–0000, 2006)
GLOBALLY, PROSTATE CANCER has become the thirdmost common cancer in men, with half a million new
cases each year, amounting to about 10% of all male cancers
(1). It is the most common cancer after skin cancer and is the
second leading cause of cancer-related death in men in the
United States. The emergence of prostate cancer as a public
health problem in developed countries has put tremendous
pressure on the health care system to provide new and ef-
fective treatments. Current understanding of cancer cell bi-
ology has allowed scientists to develop a rational approach
to combat cancer cells by using a combination of anticancer
drugs, whichwould inactivate and/ or activate, respectively,
multiple targets in cell growth-promoting and growth-
inhibitory signaling pathways. Whereas there is significant
research progress on understanding the signaling mecha-
nisms of androgen, a key growth-promoting hormone, in
prostate cancer initiation and progression, advanced pros-
tate cancer patients still suffer from inevitable relapse of the
disease after receiving the recommended treatment of an-
drogen deprivation therapy (2). Besides androgen, various
classical growth factors such as epidermal growth factor,
IGF, and TGF have also been implicated, mostly, in the
activation of prostate cancer growth (3, 4). Notwithstanding,
therapeutic targets identified by thesemore classical growth-
regulatory pathways are still in the process of successful
translation into clinical use. Clearly there is an unmet clinical
need to develop other novel therapeutic agents that can act
effectively alone and/ or in combination with androgen de-
privation therapy to halt or reverse the progression of ad-
vanced prostate cancer. Such demand has fueled the search
for novel endo-/para-/autocrine growth-promoting and
growth-inhibitory signaling pathways important in prostate
cancer pathogenesis, which may yield new therapeutic
agents or targets for antiprostate cancer drug discovery and
development. Of note, the recent success in the identification
and inhibition of Hedgehog-Gli signaling pathways in pros-
tate cancer growth has indeed opened up a new therapeutic
strategy for prostate cancer (5–8).
PDZ domain-containing protein 2 (PDZD2) {also named
KIAA0300 (9), PIN-1 (10), PAPIN (11), activated in prostate
cancer (AIPC) (12), and PDZ domain-containing protein 3
(PDZK3)}, is a six-PDZ (for PSD95, Discs-large, and ZO-1)
domain protein, which is expressed in multiple tissues (13).
Although proteins containing PDZ domains have been
shown to bind specific C-terminal protein sequences of trans-
membrane receptors or ion channels and is believed to be
involved in mediating intracellular protein-protein interac-
tions, protein scaffolding, and intracellular signaling (14, 15),
the functions of PDZD2 in humans are yet unknown. Inter-
estingly, a possible role of PDZD2 (AIPC) in prostate cancer
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pathogenesis has recently been suggested by a significant
increase in PDZD2 (AIPC) gene and protein expression in
prostate cancer tissues (12). Besides, the protein has also been
shown to be posttranslationally cleaved by a caspase-depen-
dent mechanism to form a secreted PDZ domain-containing
protein 2 (sPDZD2) (13). Taken together, it would be of
interest to determine whether sPDZD2, a posttranslationally
cleavage product of PDZD2 (AIPC), may act as a novel au-
tocrine signal important in prostate cancer pathogenesis. In
this report, we studied the expression of sPDZD2 in human
prostate cancer cells as well as the actions and mechanisms
of sPDZD2 on prostate cancer cell growth modulation.
Materials and Methods
Human cancerous/immortalized cell lines and recombinant
sPDZD2 synthesis
Human prostate cancer cell lines LNCaP.FGC (CRL-1740), DU145
(HTB-81), PC-3 (CRL-1435), and 22Rv1 (CRL-2505) as well as a human
papillomavirus 18 transformed human prostate epithelial cell line
RWPE-1 (CRL-11609) were obtained from American Type Culture Col-
lection (Manassas, VA). LNCaP and 22Rv1 cells were propagated in
RPMI 1640 medium (Life Technologies, Inc., Grand Island, NY) sup-
plemented with l-glutamine and 10% fetal bovine serum (FBS) (Life
Technologies), whereas DU145 and PC-3 cells were, respectively, prop-
agated in Eagle’s MEM (Life Technologies) and F-12 (Ham) (Life Tech-
nologies) medium supplemented with 10% FBS. RWPE-1 cells were
cultured in keratinocyte-serum free medium supplemented with 50
g/ml bovine pituitary extract and 5 ng/ml human recombinant epi-
dermal growth factor (Life Technologies). All cell lines were incubated
at 37 C with 5% CO2 humidified atmosphere. Recombinant human
sPDZD2was synthesized and purified as previously described using the
IMPACT (Intein Mediated Purification with an Affinity Chitin-binding
Tag)-CN system (New England Biolabs, Beverly, MA) (16).
Cell proliferation, viability, and apoptosis assays
DU145, PC-3, 22Rv1, and RWPE-1 cells (2  104/ml) were seeded in
96-well plates and incubated with or without 109, 108, and 107 m
purified recombinant sPDZD2 or vehicle control [20 mm Tris-HCl (pH
8), 1 mm EDTA] for 24 and 48 h before the cells were processed for cell
proliferation studies. In separate sets of experiments, DU145, PC-3,
22Rv1, and RWPE-1 cells were incubated with 10 m specific caspase-3
peptide inhibitor, Z-DEVD-FMK (BD Biosciences, San Diego, CA), 10
m-specific caspase-8 peptide inhibitor, Z-IETD-FMK (BD Biosciences),
10 m negative control peptide Z-FA-FMK (BD Biosciences), or vehicle
for 24 and 48 h. In addition, DU145, PC-3, 22Rv1, and RWPE-1 cells were
each coincubated with 10 m Z-DEVD-FMK and 108 m sPDZD2 for
48 h. Cell proliferation was measured by a tetrazolium-based Cell Titer
96AQueous assay kit (Promega,Madison,WI). Absorbance at 490 nmwas
recorded 3 h after 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) addition. The prolif-
eration of the cells was also monitored by a cell proliferation ELISA
5-bromo-2-deoxyuridine (BrdU) (colorimetric) kit (Roche, Stockholm,
Sweden), according to the manufacturer’s protocol. Cell viabilities of
LNCaP, DU145, PC-3, 22Rv1, and RWPE-1 cells, incubated with or
without 109, 108, and 107m purified recombinant sPDZD2 for 24 and
48 h, were measured by trypan blue dye exclusion assays. The number
of viable cells was counted using hemocytometers. Any apoptotic effect
on LNCaP cells induced by sPDZD2 was measured by the cell death
detection ELISAPLUS assay kit (Roche), which detects the presence of
mono- and oligonucleosomes in the cytoplasm of the cells after lysis.
Briefly, LNCaP cells (1  105/ml) were seeded in 24-well plates and
treated, under serum-free conditions, with or without 108 or 107 m
sPDZD2, in the presence or absence of 109 m dihydrotestosterone for
24 h. After treatment, cells were harvested and any apoptosis was de-
tected according to manufacturer’s instructions.
Immunoblot analyses
For studies on the expression of PDZD2 and sPDZD2, PBS-washed
native cancerous or immortalized prostate epithelial cells were incu-
bated in their respective culture media without any added FBS for 24 h
before the cells and conditioned media were collected for immunoblot-
ting with the rabbit anti-PDZD2 antibody, which has been described
previously (13). To study the effect of caspase inhibitors, the cells were
incubated with or without 10 m caspase-3 inhibitor Z-DEVD-FMK, 10
m caspase-8 inhibitor Z-IETD-FMK, or 10 m negative control peptide
Z-FA-FMKunder serum-free conditions for 48 h before immunoblotting
analysis. For studies on the effects of sPDZD2 on the expression of
proteins involved in cell cycle and apoptosis control, prostate cancer
cells were harvested in lysis buffer [10mm Tris-HCl (pH 7.4), 1% sodium
dodecyl sulfate (SDS)] after they had been incubated with or without
sPDZD2 for different time intervals. Lysates in sample buffer [0.2% SDS,
10% glycerol, 0.06m Tris-HCl (pH 6.8), 100 mm dithiothreitol, and 0.01%
bromophenol blue] were heated at 95 C for 5 min. Proteins in the
conditioned media and recombinant sPDZD2 protein standards (1012
to 107m) were concentrated 50-fold using YM-10Centricons (Millipore,
Bedford, MA). Samples (10 g) were resolved by SDS-PAGE and elec-
troblotted to polyvinyl difluoride membranes (Millipore). The blots
were blocked with 5% nonfat milk powder in TBS-T for 1 h at room
temperature and then incubated with rabbit anti-PDZD2 antibody (1:
10,000 dilution) overnight at 4 C. After washing with TBS-T, the blots
were incubated with secondary antibodies against rabbit IgG (Zymed
Laboratories, San Francisco, CA) and the signals were visualized by
enhanced chemiluminescenceWestern blotting system (Amersham Bio-
sciences, Piscataway, NJ).
To study the expression of p21CIP1/WAF1, p27KIP1, cyclin B, cyclin D,
Bad, poly(ADP-ribose) polymerase (PARP), and p53 as well as the phos-
phorylation status of p53, the blots were incubated with primary anti-
bodies against p21CIP1/WAF1 (1:500 dilution, Santa Cruz Biotechnology,
Santa Cruz, CA); p27KIP1 (1:500 dilution; Santa Cruz Biotechnology);
cyclin B (1:500 dilution; Santa Cruz Biotechnology); cyclin D (1:500
dilution; Santa Cruz Biotechnology); Bad (1:500 dilution; Santa Cruz
Biotechnology); PARP (1:500 dilution; Santa Cruz Biotechnology); p53
(1:500 dilution; Santa Cruz Biotechnology); or primary phospho-p53
antibodies against Ser6, Ser9, Ser15, Ser20, Ser37, Ser46, and Ser392
phosphorylation sites (1:1000 dilution; Cell Signaling Technology, Bev-
erly, MA) overnight at 4 C. After washing with TBS-T, the blots were
incubated with secondary antibodies against mouse IgG (Amersham
Biosciences) for p21CIP1/WAF1, p27KIP1, cyclin B, cyclinD, Bad, PARP, and
p53 antibodies or secondary antibodies against rabbit IgG (Zymed Lab-
oratories) for phospho-p53 antibodies. Blots were stripped in 25 mm
glycine buffer (pH 2.0) for 30 min for reprobing with -tubulin (1:500
dilution; Santa Cruz Biotechnology). The signals were visualized by
enhanced chemiluminescenceWestern blotting system (Amersham Bio-
sciences), and densitometric analyses of the developed blot normalized
against -tubulin were performed.
Transient reporter assay
DU145 cells (5 104/ml) were seeded onto 24-well plates. After 24 h,
the cells were transiently transfected with Fugene 6 reagent (Roche). To
each well, a mixture of 0.6 l Fugene 6, 0.2 g p21CIP1/WAF1 reporter
construct pGL3-p21pro or p27KIP1 reporter construct pGL3-p27pro, and
0.04 g Renilla luciferase reporter pRL-tk (Promega) were added.
sPDZD2 (109, 108, and 107 m) or vehicle was added directly to the
medium at one tenth dilution 24 h after transfection. After 24 and 48 h
of incubation, Dual-Luciferase reporter assay system (Promega) was
used to measure both the firefly and Renilla luciferase activities, accord-
ing to the manufacturer’s instructions. Briefly, the cells were washed
thrice with PBS. Passive lysis buffer was added to each well and was
shaken at room temperature for 15 min. Lysate (20 l) from each sample
was transferred to a 96-well plate for firefly andRenilla luciferase activity
measurement by the microplate luminometer LB96V (EG&G Berthold,
Bad Wildbad, Germany).
RNA preparation and semiquantitative RT-PCR analyses
Total RNA was extracted from DU145 cells treated with or without
109, 108, and 107 m sPDZD2 for 24 h using TRIzol (Invitrogen,
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Carlsbad, CA), and the RNA (500 ng)was then reversely transcribed into
cDNA by the SuperScript III first-strand synthesis system (Invitrogen)
following the manufacturer’s instructions. p21CIP1/WAF1 cDNA was am-
plified by PCR using specific forward primer 5-GCGATGGAACTTC-
GACTTTGT-3 and reverse primer 5-GGGCTTCCTCTTGGAGAA-
GAT-3 designed from published p21CIP1/WAF1 cDNA sequence as
reported previously (17). Similarly, p27KIP1 cDNAwas amplified by PCR
using specific forward primer 5-CCACGAAGAGTTAACCCGGG-3
and reverse primer 5-GTCTGCTCCACAGAACCGGC-3 designed
from published p27KIP1 cDNA sequence as described previously (18).
Glyceraldehyde-3-phosphate dehydrogenase cDNA was amplified by
PCR using specific forward primer 5-GCAGGGGGAGCCAAAA-
GGG-3 and reverse primer 5-TGCCAGCCCCAGCGTCAAAG-3.
cDNA amounts and cycle numbers were optimized to ensure that am-
plification was within the linear range for quantitative analysis. The
PCRs contained 2 l cDNA, 1 pmol/l primers, 1 mm deoxynucleotide
triphosphate, 1 PCR buffer, 5 mm MgCl2, and 1 U Taq DNA poly-
merase. The 40 cycles of PCR amplification were preceded by denatur-
ation at 94 C for 2 min. Each PCR cycle consisted of denaturation at 94
C for 15 sec, annealing at 55 C for 30 sec, and extension at 70 C for 1 min.
After the reaction, 10 l of the PCR products were separated on an
agarose gel [1.5% (wt/vol)]. The amplified p21CIP1/WAF1 and p27KIP1
cDNAs, normalized against glyceraldehyde-3-phosphate dehydrogenase
cDNA in the same preparations, were quantitated.
Flow cytometry
Exponentially growing cells DU145, PC-3, and 22Rv1 were seeded in
25-cm2 flasks at approximately 90% confluency. Cells were maintained
at full confluency for 72 h to synchronize cells at earlyG1. Cellswere then
released into cell cycle progression by replating onto new 25-cm2 flasks,
at approximately 30% confluency, in respective cell culture media with
or without 108 m sPDZD2. The cells were harvested at specific time
points, fixed in ethanol (70%,vol/vol) overnight, and treatedwith RNase
(10 mg/ml). Propidium iodide (250 g/ml) was then added to the
samples, mixed, and incubated in the dark for at least 15 min. Flow
cytometry was performed using the EPICS Elite ESP high-performance
cell sorter (Coulter Electronics, Miami, FL). In separate sets of experi-
ments, unsynchronized DU145, PC-3, and 22Rv1 cells were treated with
the caspase-3 inhibitor Z-DEVD-FMK (10 m) or the negative control
peptideZ-FA-FMK (10m) for 24 and 48 h. The cellswere then harvested
as described above for DNA analyses. The raw data collected were
analyzed by Modfit LT (version 2.0; Verity Software, Topsham, ME) to
eliminate aggregated cells for determination of cell cycle distribution.
Statistical and data analysis
The data were analyzed with one-way ANOVA followed by Tukey’s
test. Twogroup comparisonswere analyzed byunpaired Student’s t test.
The level of significance for all statistical analyses was set at P  0.05.
Results
Endogenous PDZD2 expression and sPDZD2 secretion in
cancerous and immortalized prostate epithelial cells
Chaib et al. (12) reported up-regulation of the full-length
PDZD2 protein in prostate cancer, but expression of the
secreted form of PDZD2, sPDZD2, has not been similarly
studied. Using a specific anti-PDZD2 antiserum that recog-
nize both the full-length and secreted forms of PDZD2 (13),
we analyzed the lysates and conditioned media from cul-
tured LNCaP, DU145, PC-3, 22Rv1, and RWPE-1 cells by
immunoblotting. Full-length PDZD2 (301 kDa) and sPDZD2
(37 kDa) were detected, respectively, in the cell lysates and
conditioned media of all the prostate cell lines (Fig. 1A). The
lack of sPDZD2 expression in the cell lysates suggests that
sPDZD2 is predominantly secreted rather than stored intra-
cellularly after its cleavage from PDZD2.
Effects of caspase inhibitors on endogenous PDZD2
expression and sPDZD2 secretion and cell growth
Full-length PDZD2 protein, which exhibits close sequence
homology to pro-IL-16, is processed and cleaved by a
caspase-dependent mechanism to generate sPDZD2 (13). In
light of the fact that cleavage of pro-IL-16 to form the cor-
responding secretory IL-16 cytokine is mediated by
caspase-3 (19), it would be of interest to determine whether
the proteolytic cleavage of full-length PDZD2 to its secreted
protein sPDZD2 is caspase-3 dependent. DU145, PC-3,
22Rv1, and RWPE-1 cells were incubated for 48 h with 10 m
Z-DEVD-FMK (a specific inhibitor of caspase-3), 10 m
Z-IETD-FMK (a specific inhibitor of caspase-8), or 10 m
Z-FA-FMK (a negative control peptide). Treatment ofDU145,
PC-3, 22Rv1, and RWPE-1 cells with Z-DEVD-FMK for 48 h
resulted in 40, 28, 44, and 50% reduction of sPDZD2 secretion
into the respective conditioned media, compared with cells
treated with Z-FA-FMK (Fig. 1B). Concomitantly, PDZD2
expression inDU145, PC-3, 22Rv1, andRWPE-1 cells showed
respective 3-, 2-, 4.4-, and 3.7-fold increases, compared with
Z-FA-FMK-treated cells (Fig. 1C). However, there were no
changes in sPDZD2 secretion and PDZD2 expression after
the cells were treated with the specific caspase-8 inhibitor
Z-IETD-FMK (10 m) for 48 h (data not shown). These data
indicated that the proteolytic cleavage of PDZD2 ismediated
by caspase-3.
To determine whether alterations in PDZD2 and sPDZD2
levels in inhibitor-treated cells are associated with any
changes in the cell growth rate, we also monitored DU145,
PC-3, 22Rv1, and RWPE-1 cell proliferation by MTS-based
assays. Interestingly, there were significant (P  0.01) in-
creases in DU145 (20.1–22.7%), PC-3 (22.9–24.8%), 22Rv1
(23.4–26%), and RWPE-1 (20.9–24.2%) cell proliferation after
the cells were treated with the caspase-3 inhibitor Z-DEVD-
FMK (10 m) for 24 and 48 h (Fig. 1, D–G). No changes in the
proportion of cells in different cell-cycle phases were de-
tected after treatment with the caspase-3 inhibitor for 24 and
48 h (data not shown). There were also no changes in the
proliferation of the cells after 24 and 48 h treatment of 10 m
caspase-8 inhibitor Z-IETD-FMK (data not shown). To fur-
ther examine whether the observed increases in cell prolif-
erationwere due to inhibition of sPDZD2 secretion,we tested
the ability of exogenously applied recombinant sPDZD2 (16)
to counteract the growth-promoting effects of the caspase-3
inhibitor. As shown in Fig. 1H, the increases in DU145, PC-3,
22Rv1, and RWPE-1 cell proliferation induced by caspase-3
inhibitor treatment were abolished by coincubating with
108 m sPDZD2. These results suggest that the antiprolif-
erative effects were predominantly mediated by sPDZD2
instead of PDZD2.
Effects of recombinant sPDZD2 on cancerous and
immortalized prostate epithelial cell growth
Recombinant sPDZD2 induced a significant (P  0.001)
concentration-dependent inhibition of cell proliferation in
DU145, PC-3, and 22Rv1 cells (Fig. 2). No significant changes
in RWPE-1 cell proliferation in response to recombinant
sPDZD2 were observed (data not shown). Treatment of
DU145 cells with 108 and 107 m sPDZD2 for 24 h resulted
balt3/zee-end/zee-end/zee01106/zee2979-06a taylormp S6 8/23/06 20:40 Art: EN-06-0207 Input-ss
Tam et al. • Prostate Cancer Growth Inhibition by Human sPDZD2 Endocrinology, November 2006, 147(11):0000–0000 3
AQ: G
AQ: H
AQ: I
F1 F2
balt3/zee-end/zee-end/zee01106/zee2979-06a taylormp S6 8/23/06 20:40 Art: EN-06-0207 Input-ss
4 Endocrinology, November 2006, 147(11):0000–0000 Tam et al. • Prostate Cancer Growth Inhibition by Human sPDZD2
in, respectively, 25.8 and 29.9% decreases in cell proliferation
(P  0.001). Treatment of PC-3 cells with 108 and 107 m
sPDZD2 for 24 h resulted in, respectively, 13.5 and 22.6%
decreases in cell proliferation (P 0.01). Treatment of 22Rv1
cells with 108 and 107 m sPDZD2 for 24 h resulted in,
respectively, 12.7 and 15.4% decreases in cell proliferation
(P  0.001). On the other hand, DU145 cell proliferation
exhibited 38.6 and 43.5% decreases (P 0.001) after the cells
were treated with 108 and 107m sPDZD2, respectively, for
48 h. PC-3 cell proliferation exhibited 23.8 and 41.6% de-
creases (P 0.001) after the cells were treated with 108 and
107 m sPDZD2, respectively, for 48 h. 22Rv1 cell prolifer-
ation exhibited 21.7 and 27.7% decreases (P 0.001) after the
cells were treated with 108 and 107 m sPDZD2, respec-
tively, for 48 h (Fig. 2, A–C). Similar antiproliferative effects
of sPDZD2 on DU145, PC-3, and 22Rv1 cells were also dem-
onstrated using the Cell Proliferation ELISA BrdU (colori-
metric) kit (Roche) (Fig. 2, D–F). No changes in DU145, PC-3,
22Rv1, and RWPE-1 cell viabilities were detected (data not
shown).
Effects of sPDZD2 on regulation of proteins involved in cell
cycle control
Given that sPDZD2 induced the strongest antiproliferative
effects on DU145 cells, compared with PC-3 and 22Rv1 cells
(Fig. 2), we selected DU145 as the principal prostate cancer
cell model to explore the intracellular mechanisms that may
mediate the growth-inhibitory effects of sPDZD2. DU145
cells were treated with 109, 108, and 107 m sPDZD2 for
48 h, and any sPDZD2-induced changes in the expression
levels of p21CIP1/WAF1, p27KIP1, p53, cyclin B, and cyclin D
were monitored. As shown in Fig. 3A, treatment of DU145
cells with 109, 108, and 107 m sPDZD2 for 48 h did not
result in any changes in the level of p27KIP1. No changes in
the expression of cyclin B and cyclin D were also observed
(data not shown). However, sPDZD2 induced changes in
p21CIP1/WAF1 and p53 in growth-inhibited DU145 cells (Fig.
3A). Treatment of DU145 cells with 108 and 107m sPDZD2
for 48 h resulted in 4.5- and 4.4-fold increases in p21CIP1/WAF1,
respectively. In correlation, DU145 cells treated with 108
and 107m sPDZD2 for 48 h, respectively, exhibited 3.9- and
3.8-fold increases in p53 expression. Of note, increased p53
expression (1.4-fold) was detected in DU145 cells after the
cells had been incubated with 108 m sPDZD2 for 12 h.
Relative to p53, the rise (2.6-fold) of p21CIP1/WAF1 expression
was delayed by 12 h in DU145 cells treated with 108 m
sPDZD2 (Fig. 3B). To further elucidate the signaling mech-
anisms of sPDZD2 inDU145 cells, the phosphorylation status
of p53 in response to sPDZD2 treatmentwas investigated.No
significant changes in the phosphorylation status of p53 at
Ser6, Ser9, Ser15, Ser20, Ser37, Ser46, and Ser392 phosphor-
ylation sites were detected in DU145 treated with 108 and
107 m sPDZD2 for 1, 4, and 8 h (data not shown). On the
other hand, no significant changes in p21CIP1/WAF1, p27KIP1,
cyclin B, and cyclinD expressionwere observed in PC-3 cells,
which showed no p53 expression (data not shown). Simi-
larly, no significant changes in p21CIP1/WAF1, p27KIP1, p53,
cyclin B, and cyclin D expression were observed in 22Rv1
cells (data not shown).
Apoptotic effects of sPDZD2 on LNCaP cells
Recombinant sPDZD2 did not induce any changes in the
viabilities of DU145, PC-3, 22Rv1, and RWPE-1 cells. How-
ever, incubation of LNCaP cells with 107m sPDZD2 for 24 h
resulted in 26.2% decrease in cell viability (P  0.001),
whereas LNCaP cell viability exhibited 14.7 and 18.6% de-
creases (P  0.001) after treatment with 108 and 107 m
sPDZD2, respectively, for 48 h (Fig. 4A). The observed de-
creases in LNCaP cell viability in response to sPDZD2 were
found to be due to apoptosis induction (Fig. 4B), asmeasured
by cell death detection ELISAPLUS assay kit (Roche). Signif-
icant (P  0.001) increases in absorbance at 405 nm, which
reflects an increase inmono- and oligonucleosomes in the cell
cytoplasm, were observed in LNCaP cells treated with 108
and 107 m sPDZD2 for 24 h. Because p53 is also a key
regulator of apoptosis besides cell cycle progression (20), we
also monitored the expression of p53 and the phosphoryla-
tion status of p53 at Ser15, Ser20, Ser37, and Ser46 phos-
phorylation sites, which are important in apoptosis control
(21), in LNCaP cells. Treatment of the cellswith 108 and 107
m sPDZD2 for 1, 2, and 4 h did not induce any changes in p53
levels and in its phosphorylation status at Ser15, Ser20, Ser37,
and Ser46 (data not shown). Interestingly, treatment of LN-
CaP cells with 108 and 107 m sPDZD2 for 24 h resulted in
respective 3.7- and 3.1-fold up-regulation in Bad expression.
In addition, treatment of LNCaP cells with 108 and 107 m
sPDZD2 for 48 h increased the expression of Bad by 2.6- and
2.1-fold, respectively (Fig. 4C). The cleavage of PARP, which
serves as an early specific marker of apoptosis, was also
observed after treatment of LNCaP cells with 108 and 107
m sPDZD2 for 24 and 48 h (Fig. 4C). In the presence of 109
m dihydrotestosterone, the apoptotic effects induced by 108
and 107 m sPDZD2 were significantly reduced (data not
shown), indicating that androgen may confer protection
against sPDZD2-induced apoptosis in LNCaP cells.
Effects of sPDZD2 on p21CIP1/WAF1 and p27KIP1
transcription
To determine whether the elevated p21CIP1/WAF1 protein ex-
pression was caused by an increase in p21CIP1/WAF1 gene tran-
FIG. 1. Expression and secretion of PDZD2/sPDZD2 in cancerous and immortalized prostate epithelial cells and the effects of caspase-3 inhibitor
Z-DEVD-FMK on PDZD2/sPDZD2 expression and secretion and cell growth. A, The presence of PDZD2 and sPDZD2 in cell lysates and
concentrated conditioned media of LNCaP (lane 1), DU145 (lane 2), PC-3 (lane 3), 22Rv1 (lane 4), and RWPE-1 (lane 5) cells were detected by
immunoblotting, using rabbit anti-PDZD2 antiserum (1:10,000 dilution). B, Detection of sPDZD2 secretion using rabbit anti-PDZD2 antiserum
in the concentrated conditioned media harvested from DU145, PC-3, 22Rv1, and RWPE-1 cells treated with () or without () 10 M
Z-DEVD-FMK for 48 h. C, Detection of PDZD2 expression using rabbit anti-PDZD2 antiserum in lysates of DU145, PC-3, 22Rv1, and RWPE-1
cells treated with () or without () 10 M Z-DEVD-FMK for 48 h. RWPE-1 (D), DU145 (E), PC-3 (F), and 22Rv1 (G) cells were treated with
10 M Z-DEVD-FMK, 10 M Z-FA-FMK, or vehicle for 24 and 48 h. H, DU145, PC-3, 22Rv1, and RWPE-1 cells were incubated with 10 M
Z-DEVD-FMK, 10MZ-FA-FMK, 10MZ-DEVD-FMKplus 108 M sPDZD2, or vehicle for 48 h. Cell proliferationwasmonitored byMTS assays.
Data are shown as mean  SE. *, P  0.01 and ** P  0.001, compared with control.
balt3/zee-end/zee-end/zee01106/zee2979-06a taylormp S6 8/23/06 20:40 Art: EN-06-0207 Input-ss
Tam et al. • Prostate Cancer Growth Inhibition by Human sPDZD2 Endocrinology, November 2006, 147(11):0000–0000 5
F3
F4
scription induced by sPDZD2, we monitored p21CIP1/WAF1 pro-
moter activity in DU145 cells in response to sPDZD2 treatment
using luciferase reporter assays. Treatment of DU145 cells with
108 and 107m sPDZD2 for 24 h resulted in, respectively, 1.4-
and 1.8-fold increases (P  0.01) in p21CIP1/WAF1 promoter ac-
tivity. Similarly, treatment of DU145 cells with 108 and 107m
FIG. 2. Effects of sPDZD2 on prostate cancer cell proliferation. DU145 (A), PC-3 (B), and 22Rv1 (C) cells were treated with 109, 108, and
107 M recombinant sPDZD2 for 24 and 48 h. The effects of sPDZD2 on cell proliferation were monitored by MTS assays. The proliferation of
DU145 (D), PC-3 (E), and 22Rv1 (F) cells treated with 109, 108, and 107 M recombinant sPDZD2 for 24 and 48 h was also monitored by cell
proliferation ELISA BrdU (colorimetric) assays. Data are shown as mean  SE. *, P  0.01 and **, P  0.001, compared with control.
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sPDZD2 for 48h resulted in1.4- and2.2-fold increases (P0.01)
in p21CIP1/WAF1 promoter activity, respectively (Fig. 5A). No
significant changes in the promoter activity of p27KIP1 could be
detected (Fig. 5B). The p21CIP1/WAF1 and p27KIP1 promoter ac-
tivity changes induced by sPDZD2 were in good correlation
with sPDZD2-induced changes in p21CIP1/WAF1 and p27KIP1
mRNA levels as quantitated by RT-PCR. Treatment of DU145
cells with 108 and 107m sPDZD2 for 24 h resulted in 2.6- and
2.9-fold increases in p21CIP1/WAF1 mRNA levels, whereas no
changes in p27KIP1 mRNA could be detected (Fig. 5C).
Effects of sPDZD2 on cell cycle progression
The growth suppressive effects of sPDZD2 on DU145 cells
were monitored by flow cytometry. Treatment of synchro-
nized DU145 cells with 108 m sPDZD2 delayed the entry of
the cells to the S phase of cell cycle. Without sPDZD2 treat-
ment, the synchronized DU145 cells reenter into S phase by
12 h after replating, as reflected by an increase in the per-
centage of S phase cells from 22.1 to 38.9% (Fig. 6A). In
contrast, most of the sPDZD2-treated cells remained in the
G0/G1 phase, and no significant increase in the percentage of
S phase cells was observed until 48 h after replating (Fig. 6B).
Similar to DU145 cells, untreated synchronized PC-3 and
22Rv1 cells reenter into S phase by 12 h after replating, as
reflected by an increase in the percentage of S phase cells
from 25.4 to 34.8% and from 25.4 to 33.7%, respectively,
whereas most of the sPDZD2-treated PC-3 and 22Rv1 cells
remained in the G0/G1 phase until 48 h after replating (data
not shown).
Discussion
In this communication, we demonstrated the endogenous
intracellular expression of PDZD2 and extracellular secretion
of its cleavage product sPDZD2 in human prostate cancer
LNCaP, DU145, PC-3, and 22Rv1 cell lines as well as the
immortalized RWPE-1 cells (Fig. 1A). Furthermore, the
cleavage of sPDZD2 from its precursor PDZD2 in prostate
cancer cells is shown to be mediated by a caspase-3-depen-
dent mechanism, similar to that reported for the proteolytic
processing of IL-16 from pro-IL-16 (19) (Fig. 1, B and C).
Importantly, inhibition of endogenous sPDZD2 production
and secretion by DU145, PC-3, 22Rv1, and RWPE-1 cells via
the specific caspase-3 inhibitor Z-DEVD-FMK resulted in
increased cell proliferation, which can be abrogated by sup-
plementation with exogenous recombinant sPDZD2 (Figs. 1,
D–H). The results suggest that endogenous sPDZD2 may
exert an autocrine physiological antiproliferative action on
human prostate cancer cells. Although we estimated the
concentration of endogenous sPDZD2 in the conditioned cell
culturemedia to be in the range of 1010 to 1011m, it remains
to be determined whether this reflects the actual concentra-
tion of sPDZD2 in human interstitial fluid or plasma. Not-
withstanding this limitation of the yet-unknown physiolog-
ical concentration of sPDZD2, it is noteworthy that the
predicted antiproliferative actions can indeed be induced in
the cancerous prostate epithelial cells by treating them with
recombinant sPDZD2 (Fig. 2), which provide support for our
postulation that sPDZD2 may function as an autocrine
growth suppressor for human prostate cancer cells. It is also
evident from our studies that sPDZD2 can suppress prostate
cancer cell growth by not only antiproliferation as shown in
DU145, PC-3, and 22Rv1 cells but also apoptosis induction in
LNCaP cells (Fig. 4). Together with the reported up-regula-
tion of gene and protein expression of PDZD2, also known
as AIPC, in human prostate cancer tissues (12), our data
indicate that sPDZD2, a proteolytic secretory product of
PDZD2, may indeed play an important role in growth dys-
regulation in prostate cancer tumorigenesis and progression.
Flow cytometric data have indicated that antiproliferative
effects of sPDZD2 on DU145, PC-3, and 22Rv1 cells are
largely mediated via slowing the entry of these cancer cells
into the S phase of the cell cycle (Fig. 6). In DU145 cells, we
found an increase in p53 protein expression, followed by
correlative increases in the gene and protein expression of
p21CIP1/WAF1, which is an important p53 transcriptional tar-
get (22) (Figs. 3 and 5). The observed slowing of DU145 cell
cycle progression from G1 to S in response to sPDZD2 can
thus be adequately explained by sPDZD2-induced up-reg-
ulated gene and protein expression of p21CIP1/WAF1, which is
a well-known cyclin-dependent kinase inhibitor crucial for
G1 mitotic checkpoint regulation (23). Interestingly, the
DU145 cell line, in which more than 90% of the cells show
positive immunoreactivity for p53 (24), carries two mutant
p53 alleles producing p53223Leu and p53274Phe, whose trans-
activation abilities on p53-responsive genes differ from each
other (25). It has been shown that p53223Leu was as active as
wild-type p53 in transactivation of p53-responsive genes
such as p21CIP1/WAF1, whereas p53274Phe has no detectable
transactivation activity on those genes in a direct transacti-
vation assay (25). Apparently sPDZD2 has the ability to
activate p53223Leu-p21CIP1/WAF1 signaling pathway in DU145
cells to mediate its cytostatic actions observed in the present
study, although the remote possibility of p21CIP1/WAF1 acti-
vation by p53-independent mechanisms may still need to be
FIG. 3. Effects of sPDZD2 on p21CIP1/WAF1, p27KIP1, and p53 expres-
sion. A, DU145 cells were treated with 109, 108, and 107 M recom-
binant sPDZD2 for 48 h, and p21CIP1/WAF1, p27KIP1, and p53 levels were
detected by immunoblotting. B, Time-course studies of p21CIP1/WAF1 and
p53 expression afterDU145 cellswere incubatedwith () orwithout ()
108 M recombinant sPDZD2 for various time intervals.
balt3/zee-end/zee-end/zee01106/zee2979-06a taylormp S6 8/23/06 20:40 Art: EN-06-0207 Input-ss
Tam et al. • Prostate Cancer Growth Inhibition by Human sPDZD2 Endocrinology, November 2006, 147(11):0000–0000 7
F5
F6
FIG. 4. Effects of sPDZD2 on LNCaP
cell growth. A, LNCaP cells were
treated with 109, 108, and 107 M re-
combinant sPDZD2 for 24 and 48 h. The
effects of sPDZD2 on cell viability were
monitored by trypan blue dye exclusion
assays. B, Cell death detection ELISAP-
LUS assay kit (Roche) was used to de-
termine the apoptotic effects of sPDZD2
on LNCaP cells. After treatment of the
cells with 108 and 107 M recombinant
sPDZD2 for 24 h, the cells were lysed
and the presence of nucleosomes in the
cytoplasm was detected by measuring
absorbance values at 405 nm. Data are
shown as mean  SE. **, P  0.001,
compared with control. C, LNCaP cells
were treated with 109, 108, and 107
M recombinant sPDZD2 for 24 and 48 h.
The level of Bad and the processing of
PARP were monitored by immunoblot-
ting.
balt3/zee-end/zee-end/zee01106/zee2979-06a taylormp S6 8/23/06 20:40 Art: EN-06-0207 Input-ss
8 Endocrinology, November 2006, 147(11):0000–0000 Tam et al. • Prostate Cancer Growth Inhibition by Human sPDZD2
considered in future studies. In an attempt to further define
the mechanisms involved in p53 up-regulation and activa-
tion in DU145 cells by sPDZD2, we examined any sPDZD2-
induced changes in phosphorylation at specific serine resi-
dues of p53 in DU145 cells, using a panel of antibodies
against phospho-p53 (Ser6, Ser9, Ser15, Ser20, Ser37, Ser46,
and Ser392). Intriguingly, we were unable to detect any sig-
nificant sPDZD2-induced changes in p53 phosphorylation at
the aforementioned serine residues in DU145 cells. Because
active p53 is subject to a diverse array of covalent posttrans-
lational modifications, any sPDZD2-induced changes in pro-
tein phosphorylation at sites outside those examined and in
FIG. 5. Effects of sPDZD2 on p21CIP1/WAF1
and p27KIP1 gene transcription. The promoter
activities of p21CIP1/WAF1 (A) and p27KIP1 (B)
were monitored by luciferase reporter assays
after DU145 cells were treated with 109,
108, and 107 M recombinant sPDZD2 for 24
and 48 h.Data are shown asmean SE. *,P
0.01 and **,P0.001, comparedwith control.
C, Total RNAwas extracted fromDU145 cells
treated with or without 109, 108, and 107
M recombinant sPDZD2 for 24 h using TRIzol
(Invitrogen) and was reversely transcribed
into cDNA by using the SuperScript III first-
strand synthesis system (Invitrogen). After
40 cycles of amplification by PCR, the PCR
products were separated by 1.5% agarose gel.
GAPDH, Glyceraldehyde-3-phosphate dehy-
drogenase.
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other modifications such as acetylation, ribosylation, O-gly-
cosylation, ubiquitination, and sumoylation (21) will need to
be examined in future studies.
Given that p53 is an important node that integrates diverse
oncogenic and DNA damage signals to mediate cytostasis
and apoptosis (26), we also examinedwhether p53 activation
is likely to be a commonmechanism through which sPDZD2
induces its antiproliferative or apoptotic effects on other
prostate cancer PC-3, 22Rv1, and LNCaP cells. Of note, we
could not detect any expression of p53 in the PC-3 cell line,
which has been shown to harbor a frameshift deletion mu-
tation in its single p53 allele, causing a stop signal at codon
169 of the protein (27). Moreover, sPDZD2 induced no sig-
nificant changes of p21CIP1/WAF1 and p27KIP1 in PC-3 cells.
The above findings suggested that, distinct fromDU145 cells,
the mechanism mediating sPDZD2-induced antiprolifera-
tion in PC-3 cells is p53 independent. Similarly, no significant
changes in p21CIP1/WAF1, p27KIP1, and p53 were induced by
sPDZD2 in the 22Rv1 cell line, which probably expresses a
wild-type p53 in addition to a mutated p53331Arg, when cul-
tured under standard conditions (24). Clearly further studies
were needed to determine the importance of p53 in the an-
tigrowth mechanisms induced by sPDZD2 on 22Rv1 cells.
Whereas sPDZD2 inducedLNCaP cells to undergo apoptosis
as shown by increases in Bad expression and PARP cleavage
(Fig. 4C), no significant changes in total cellular p53 were
observed, despite the fact that the LNCaP cell line is known
to express wild-type p53 (24, 28) because its expression can
be up-regulated by DNA damage signal induced by irradi-
ation (28). Moreover, sPDZD2 did not induce, in LNCaP
cells, any changes in p53 phosphorylation at Ser15, Ser20,
Ser37, and Ser46, which are phosphorylation sites that are
important in apoptosis control by p53 (21). These results
suggest that the apoptotic effect of sPDZD2 on LNCaP cells
is probably mediated through p53-independent Bad up-
regulation (29).
In summary, we have obtained evidence to support the
existence of PDZD2/sPDZD2-mediated autocrine growth
suppressive signaling pathways in human prostate cancer
cells. The p53-dependent and p53-independent mechanisms
of sPDZD2 in growth inhibition of DU145, PC-3, 22Rv1, and
LNCaP prostate cancer cell lines observed in our studies
indicate that PDZD2/sPDZD2 signaling may use different
and, perhaps, new signal transduction pathways of the in-
trinsic tumor suppressive network in prostate cancer in dif-
ferent developmental or progression stages to mediate its
growth suppressor actions.Detailed characterization of these
PDZD2/sPDZD2 signaling pathways and identification of
the membrane receptor(s) involved may yield not only new
therapeutic targets for antiprostate cancer drug discovery
and development but also provide novel ways, such as har-
nessing therapeutically the latent tumor-suppressive poten-
tial of an endogenous autocrine signaling protein like
sPDZD2, to inhibit prostate cancer growth. Besides the po-
tential therapeutic implications mentioned above, unravel-
ing the autocrine signaling mechanisms of PDZD2/sPDZD2
in prostate cancer growth suppression will help to increase
our understanding of the physiological growth-inhibitory
FIG. 6. Effects of sPDZD2 on cell cycle progression in DU145 cells. DU145 cells were synchronized by confluency. After replating the cells at
approximately 30% confluency, in Eagle’sMEMwith or without 108 M recombinant sPDZD2, the cells were harvested at specific time intervals.
After the cells were harvested and fixed, they were treated with RNase and propidium iodide for DNA analyses. Using the EPICS Elite ESP
high-performance cell sorter (Coulter Electronics), histograms of DU145 cells treated with vehicle (A) or sPDZD2 (B) were obtained. The raw
data collected were analyzed by Modfit LT (version 2.0), and arrows indicate increases in the percentage of S-phase cells suggesting S-phase
entry.
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networks contributed by vitamin D3/vitamin D receptor (30)
and melatonin/MT1 receptor (31–34) signaling at the endo-
crine level and fatty acid metabolites/peroxisome prolifera-
tor-activated receptor- (35, 36) signaling at the paracrine
level.
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